Supreme Court Opinions
Welcome to Supreme Court Opinions. In this episode, you’ll hear the Court’s opinion in Hikma Pharmaceuticals USA Inc. v Amarin Pharma, Inc. In this case, the court considered these issues. 1. When a generic drug manufacturer excludes a patented use from its label, can it still be liable for inducing infringement if it calls its product a “generic version” of the brand-name drug and cites publicly available information about the brand-name drug’s sales? 2. Can a patent infringement complaint survive dismissal if it does not allege that the defendant made any statement specifically instructing or encouraging the patented use? The case was decided on June 4, 2026. The opinion is presented here in its entirety, but with citations omitted. If you appreciate this episode, please subscribe. Thank you.
280 episodes
Comments
0Be the first to comment
Sign up now and become a member of the Supreme Court Opinions community!